Newly publsihed data from the MABEL study shows Erbitux plus Irinotecan is effective in Colorectal cancer… more →
Kinase Newssmnewsletters wrote 6 months ago: According to the bulk of the data, alterations in TOP2A—not HER2—are “the important predictive … more →
calvininjax wrote 10 months ago: By Calvin Palmer A three-year-old boy has written to British Prime Minister Gordon Brown pleading fo … more →
bmirtsching wrote 1 year ago: CORT has conducted research and treatment studies with the monoclonal anti-EGFR (anti-epidermal grow … more →
crimsoncanary wrote 1 year ago: Newly publsihed data from the MABEL study shows Erbitux plus Irinotecan is effective in Colorectal c … more →
crimsoncanary wrote 1 year ago: Eli Lilly has announced that it will acquire ImClone Systems through an all cash tender offer of $70 … more →
crimsoncanary wrote 1 year ago: Five year data presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Meet … more →
crimsoncanary wrote 1 year ago: ImClone Systems have announced that erbitux (cetuximab) has been commercially launched in Japan for … more →
crimsoncanary wrote 1 year ago: Data presented at the European of Medical Oncology (ESMO) show that Erbitux, plus FOLFIRI, continued … more →
crimsoncanary wrote 1 year ago: Merck Serono has submitted an EMEA application for Erbitux (cetuximab) for use in the firstline trea … more →
crimsoncanary wrote 1 year ago: Imclone and BMS have announced the publication of Phase III results of Erbitux (cetuximab) plus pla … more →
crimsoncanary wrote 1 year ago: ImClone Systems has submitted an sBLA to the US FDA to broaden the use of ERBITUX (cetuximab) to inc … more →
crimsoncanary wrote 1 year ago: ImClone have announced that Phase III results show erbitux (cetuximab) in combination with a taxane … more →
crimsoncanary wrote 1 year ago: Merck Serono have received EU approval for Erbitux in EGFR expressing, KRAS wild-type metastatic col … more →
crimsoncanary wrote 1 year ago: ImClone Systems have announced that Erbitux (cetuximab) has been approved in Japan for use in treati … more →
crimsoncanary wrote 1 year ago: Merck KGaA (Merck-Serono) has initiated a Phase III study of Erbitux in combination with Xeloda and … more →
crimsoncanary wrote 1 year ago: The UK NICE have announced that review of Avastin and Erbitux for the following indications have bee … more →
crimsoncanary wrote 1 year ago: Merck Serono have submitted a EU application for Erbitux (cetuximab) to be used as a first line trea … more →
bmirtsching wrote 1 year ago: Gastric cancer is the fourth most common cancer worldwide, and the second leading cause of death wor … more →
bmirtsching wrote 1 year ago: The results of the FLEX study of cisplatin + vinorelbine (Navelbine) with or without cetuximab (Erbi … more →